1. Overall Market Scale
1.1 Global Market Overview
As a core auxiliary product in the pharmaceutical and health product industries, the global pharmaceutical hollow capsule market has maintained steady growth driven by the expanding pharmaceutical market and the rising demand for dietary supplements. By 2025, the global market size of pharmaceutical hollow capsules is estimated to reach USD 5.8-7.2 billion, with an annual compound growth rate (CAGR) of 6.2%-7.5% from 2020 to 2025.
The Asia-Pacific region, led by China, has become the world's largest production and consumption base for hollow capsules, contributing approximately 35% of the global production capacity and 32% of the global market share. Europe and North America follow closely, accounting for 28% and 25% of the global market share respectively, mainly driven by high demand for high-end pharmaceutical products (such as enteric-coated capsules and sustained-release capsules) and strict regulatory requirements for product quality.
1.2 China's Market Scale: The World's Largest Producer and Consumer
China dominates the global hollow capsule industry with its massive production capacity and consumption volume:
Production Capacity: By 2025, China's annual production capacity of pharmaceutical hollow capsules exceeds 400 billion pieces, accounting for over 50% of the global total production capacity. The production capacity is mainly distributed in provinces such as Jiangsu, Shandong, Zhejiang, and Guizhou, where industrial clusters have formed with complete upstream and downstream supply chains (e.g., raw material supply of gelatin and HPMC, production equipment manufacturing).
Market Size: In 2025, China's pharmaceutical hollow capsule market size is expected to reach RMB 8.5-15 billion (equivalent to approximately USD 1.18-2.05 billion based on the average 2025 exchange rate). The wide range of market size data is mainly due to differences in statistical standards among research institutions: some include only pharmaceutical-grade hollow capsules, while others cover both pharmaceutical-grade and food-grade products. According to the China Pharmaceutical Packaging Association (CPPA), the market size of pharmaceutical-grade hollow capsules in China was approximately RMB 9.2 billion in 2024, and it is expected to grow to RMB 10.5 billion in 2025.
Demand and Capacity Utilization: Despite the large production capacity, China's actual annual demand for pharmaceutical hollow capsules is about 380 billion pieces, resulting in a capacity utilization rate of less than 70%. The overcapacity issue has become a key challenge for the industry, leading to intense price competition. From 2019 to 2024, the average gross profit margin of China's hollow capsule enterprises dropped from 28% to 16.3%, with small and medium-sized enterprises (SMEs) facing greater pressure (some even having a gross profit margin of less than 10%).
2. Competitive Landscape
2.1 Market Concentration: Pyramid Structure Dominated by Leading Enterprises
China's hollow capsule industry presents a "pyramid-shaped" competitive pattern with distinct levels of market concentration:
Top-Tier Enterprises (10% of total enterprises): The top 10 enterprises account for 57.3% of the market share, with leading enterprises such as Qingdao Yiqing Biology Co., Ltd. (market share 13.6%) and Jiangsu Lifan Capsule Co., Ltd. (market share 9.8%) taking the lead. These enterprises have advantages in scale, technology, and quality: for example, Qingdao Yiqing Biology has an annual production capacity of 150 billion pieces, equipped with fully automated production lines (single-machine daily output up to 2.6 million pieces) and a complete quality control system (meeting both Chinese Pharmacopoeia and FDA/EMA standards), making its products export to over 30 countries and regions.
Mid-Tier Enterprises (30% of total enterprises): These enterprises have an annual production capacity of 10-50 billion pieces, focusing on regional markets or specific product segments (e.g., HPMC plant-based capsules). Their market share totals approximately 30%, and they mainly compete with top-tier enterprises in the mid-end market.
Low-Tier Enterprises (60% of total enterprises): Most of these are SMEs with an annual production capacity of less than 10 billion pieces, relying on low-cost strategies to occupy the low-end market. Due to backward production technology and insufficient quality control capabilities, some enterprises have been eliminated in recent years due to stricter regulatory inspections (e.g., inspections on heavy metal residues and solvent residues).
2.2 Regional Competitive Distribution
2.2.1 Domestic Regional Pattern in China
East China (Jiangsu, Shandong, Zhejiang): As the core production base of China's hollow capsule industry, it accounts for 62% of the national production capacity. Jiangsu Province, in particular, has a concentration of leading enterprises (e.g., Jiangsu Lifan Capsule) and supporting industries (e.g., gelatin suppliers in Nanjing).
South China (Guangdong, Fujian): Focuses on high-end products such as plant-based capsules and functional capsules, with an annual production capacity accounting for 18% of the national total. Enterprises here have strong export capabilities, with products mainly sold to Southeast Asia and Europe.
Central and Western China (Guizhou, Sichuan): Emerging production bases, relying on low labor and land costs to attract investment from eastern enterprises. For example, Guizhou Guangdeli Capsule Co., Ltd. invested RMB 300 million to build a production base with an annual capacity of 24 billion pieces, which is expected to further expand the production capacity of the central and western regions.
2.2.2 Global Competitive Pattern
China: As the world's largest producer, China's export volume of hollow capsules accounts for 40% of the global trade volume. However, most exported products are mid-low-end gelatin capsules, while high-end products are still dominated by European and American enterprises.
Europe: Enterprises such as Lonza Group (Switzerland) and Capsugel (U.S.-owned, with major production bases in Europe) lead the global high-end market, focusing on functional capsules (e.g., temperature-sensitive capsules, multi-release capsules) and plant-based capsules. Their products have high added value, with a gross profit margin of over 35%.
North America: Mainly dominated by local enterprises and European subsidiaries, with strict quality requirements for imported hollow capsules. In 2025, the U.S. launched anti-dumping and countervailing (AD/CVD) investigations against hollow capsule imports from China, Brazil, India, and Vietnam, which will affect the export of Chinese enterprises to the U.S. market (China's annual export volume to the U.S. is approximately USD 43.6 million).
2.3 Key Competitive Factors
Quality and Compliance: With the implementation of stricter standards (e.g., China's 2025 Pharmacopoeia, FDA's cGMP), enterprises with complete quality control systems (e.g., raw material traceability, residue detection) have a competitive advantage.
Technology and Product Innovation: The development of plant-based capsules (e.g., HPMC, potato starch capsules) and functional capsules has become a key competition point. Enterprises with independent R&D capabilities (e.g., Shandong Heda Co., Ltd. in HPMC capsule technology) can occupy the high-end market.
Scale and Cost Control: Large-scale enterprises can reduce unit costs through bulk procurement of raw materials and automated production, while SMEs face cost pressure due to small procurement volumes and low production efficiency.
